Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs [MSNBC.com]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: MSNBC.com
Key PointsIn this articleSignage for Novartis AG at a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.Bloomberg | Bloomberg | Getty ImagesThe stock pared gains slightly to trade up 3.2% by 1:50 p.m. London time.Novartis' net sales rose 11% in the first three months of the year, while core operating income increased 22% over the same period.CEO Vas Narasimhan said the growth solid across all its major brands, which include blockbuster heart failure drug Entresto and psoriasis drug Cosentyx."Our performance was broad-based, across all key growth brands and geographies, allowing us to raise guidance for the full year 2024," he said in a statement.The company said 2024 net sales are now anticipated to pick up by a high single- to low double-digit percentage, up from a previous outlook of mid-single-digit growth.The drugmaker has also revised its expectations for core operating income, now set to expand by a low double-digit to mid-teens percent
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Fragile X Syndrome Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status [Yahoo! Finance]Yahoo! Finance
- UPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billion [Yahoo! Finance]Yahoo! Finance
- Novartis to buy Mariana Oncology for $1B upfront [Seeking Alpha]Seeking Alpha
- Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer [Yahoo! Finance]Yahoo! Finance
- The Global Market for Smart Inhalers, 2018-2023 and 2024-2033 - Novartis, AstraZeneca, GlaxoSmithKline, 3M Health Care, and Boehringer Ingelheim International Dominate the $1.62 Billion Industry [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- NVS's page on the SEC website